Cell Rep:肠癌干细胞被调节引发肠癌的分子机理

2015-02-10 佚名 生物谷

近日,发表在国际杂志Cell Reports上的一篇研究论文中,来自美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research Institute)的研究人员通过研究发现了一种新型的精细干细胞信号通路,如果该通路被打断则会引发肠道肿瘤,相关研究或可帮助理解干细胞如何引发肿瘤,并且可以帮助研究人员寻找靶向作用干细胞的分子来抑制肠癌的发生、发展和复发。

近日,发表在国际杂志Cell Reports上的一篇研究论文中,来自美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research Institute)的研究人员通过研究发现了一种新型的精细干细胞信号通路,如果该通路被打断则会引发肠道肿瘤,相关研究或可帮助理解干细胞如何引发肿瘤,并且可以帮助研究人员寻找靶向作用干细胞的分子来抑制肠癌的发生、发展和复发。

Jorge Moscat博士指出,大量证据表明,癌症干细胞对于癌症发生、发展、转移、复发以及产生耐药性都非常关键,本文这项研究揭示了调节干细胞的一种级联信号,并且研究者还发现该通路对于设计新型靶向抗癌疗法非常必要。研究者表示,一种名为C-zeta (PKC-zeta)的蛋白激酶正常情况下可以通过下调两种信号通路:β-连环蛋白和Yap来抑制干细胞的活性;此前研究发现,PKC-zeta可以扮演一种肿瘤抑制子的角色来维持肠道干细胞的自我平衡,而当前研究正揭示了上述过程发生的分子机制

肠道组织由单层的上皮细胞所覆盖,其每隔3-5天都会更新,而移除肠道干细胞的细胞库往往需要被调节来维持自我平衡;研究者说道,如果干细胞活性增加,特别是在肠道缺失PKC-zeta时,就很有可能引发肠道肿瘤。利用一种遗传工程化的患肠癌的小鼠模型进行研究,研究人员就可以在人类结肠腺癌组织中PKC-zeta、β-连环蛋白和Yap致癌特性,而β-连环蛋白和Yap则是PKC-zeta功能的潜在靶点,其为后期开发抗癌疗法也带来了极大帮助。

最后研究者说道,本文研究为通过阻断引发肿瘤的新型通路,从而帮助开发预防及抑制肠癌发生的新型策略提供了新的思路和研究基础,也为开发促进急性或慢性损伤后促进肠道细胞再生的新技术诞生提供了保证。

doi:10.1016/j.celrep.2015.01.007

PMC:

PMID:

Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ

Victoria Llado, Yuki Nakanishi, Angeles Duran, Miguel Reina-Campos, Phillip M. Shelton, Juan F. Linares, Tomoko Yajima, Alex Campos, Pedro Aza-Blanc, Michael Leitges, Maria T. Diaz-Meco, Jorge Moscat.

Disturbing the homeostasis of the stem cell pool can go two ways--it can either reduce intestinal epithelial cell regeneration or increase the proliferation of stem cells," said Diaz-Meco. "Cancer is produced by the accumulation of mutations in critical genes that control central mechanisms of cell growth. Stem cells are a 'permanent' population in the intestine and a reservoir for those mutations. Therefore, if stem cell activity is increased, as in the case of intestines deficient in PKC-zeta, then the likelihood of developing tumors is much higher, and when the tumor is initiated it becomes more aggressive.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]
    2015-05-02 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]
    2015-02-23 orthoW

    不错的文章,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    以阅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1922338, encodeId=9fc5192233834, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sun Oct 11 23:31:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959273, encodeId=e01719592e3d8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 02 09:31:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869022, encodeId=d4cc186902200, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Mar 13 18:31:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16763, encodeId=473d16e6393, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Mon Feb 23 11:37:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15801, encodeId=a8b01580130, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:07:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544967, encodeId=138d154496e9c, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Thu Feb 12 00:31:00 CST 2015, time=2015-02-12, status=1, ipAttribution=)]

相关资讯

韩忠朝:黏上干细胞30年

干细胞">干细胞技术产业化是韩忠朝最后一项事业,这位2014年国家科技进步奖一等奖得主,最希望的是中国能有在国际上有一席之地的干细胞高科技企业。“现在就想怎么样架一座桥,把自己的、别人的一些好的科研成果,转化成科技产品、社会效益”。 1月9日,国家科学技术奖励大会在北京人民大会堂举行。中国医学科学院北京协和医学院教授、国家干细胞工程技术研究中心主任韩忠朝与军事医学科学院联合完成的“成体

STM:基因改造过的诱导性多功能干细胞(iPSCs)可治疗隐性遗传营养不良型大疱性表皮松解症(RDEB)

隐性遗传营养不良型大疱性表皮松解症(RDEB) 是一种遗传疾病。它是由于VII型胶原的编码基因变异导致的。RDEB患者的皮肤很脆弱并且很容易在接收到压力时起水疱。特别是对于RDEB这种在现阶段没有有效治疗的疾病,使用诱导性多功能干细胞(iPSCs)有从根本上改变疾病细胞治疗的潜力。为了证明诱导性多功能干细胞(iPSCs)可以治疗RDEB,研究者们从有VII型胶原基因(Co17a1)变异的小鼠中提取

Science:癌症干细胞,癌症泰斗的豪赌

麻省理工的Robert Weinberg是世界上最著名的癌症生物学家之一。他发现了第一个人类癌基因Ras和第一个抑癌基因Rb,其杰出工作已经成为肿瘤研究领域乃至整个医学生物学领域的重要里程碑。“我在这一行已经四十年了,我们研究的许多东西最终在临床上都没什么用,” Weinberg说。但现在,这位72岁高龄的癌症泰斗重新乐观起来。 据Science介绍,Weinberg为一个大胆的癌症理论赌上了

EMA批准干细胞治疗产品 用于眼角膜疾病治疗

根据汤森路透Bioworld报道,EMA首次为干细胞治疗药品的上市亮起了绿灯,这也是EMA连续第三年在药品的年度审批通过量上呈现增加态势。虽然2014总共获批的药物有82个,仅比2013年的81个多1个,但是对比于2012年的57个,应该可以说是显著增加。第一个被EMA批准通过的干细胞治疗药物名为Holoclar,该药物被推荐用于治疗由严重眼部化学或物理灼伤引起的眼角膜干细胞缺失,由意大利制药公司

美科学家希望借干细胞靶向药物消灭癌症

Robert Weinberg是当今世界最有名的癌症生物学家之一,他在区分标志癌症发展的基因方面曾做出先驱工作。他见证过来来往往各种癌症疗法带来的希望。“无论好坏,我在这个领域已经工作了40年。但我们过去做过的许多工作已经在临床上被证明是没有用的。”如今迈入古稀之年,已是72岁高龄的他重新恢复了乐观。“这是我真正意义上第一次处于研发一种或多种有效试剂的岗位上,这些疗法将真正惠及癌症患者。”

STM:未成熟的干细胞可修复肺损伤

目前,在急性肺损伤中存活下来的病人的肺部功能都可恢复,这意味着成人的肺组织可在某种程度上再生。根据不同肺损伤的成因或严重性,许多不同种类的始祖细胞都可成功帮助小鼠肺部再生,这些始祖细胞包括肺泡II型细胞以及气道末梢肝细胞。近日,Vaughan和他的团队发现未成熟的隐形内皮谱系始祖细胞(LNEP cells)可以恢复因流感病毒或博来霉素而引起的肺损伤。LNEP细胞在正常小鼠的肺末梢中是处于休眠状态的